Research Output
Therapeutic potential of Tregs to treat rheumatoid arthritis
  There is accumulating evidence for regulatory T cell defects in rheumatoid arthritis and that some biologic interventions, in particular anti-TNF, can target this population. Despite the challenges in defining regulatory T cells in patients, there are a number of approaches currently being developed to utilise their potent immunosuppressive properties. Through genetic manipulation Tregs can be generated ex vivo or in vivo that target antigens present in the inflamed joint. Here we discuss these approaches, their refinement to restore tolerance in patients with rheumatoid arthritis, and strategies to prevent their conversion towards a Th17 phenotype.

  • Type:

    Article

  • Date:

    30 June 2011

  • Publication Status:

    Published

  • Publisher

    Elsevier BV

  • DOI:

    10.1016/j.smim.2011.07.004

  • Cross Ref:

    S1044532311000601

  • ISSN:

    1044-5323

  • Library of Congress:

    QR180 Immunology

  • Dewey Decimal Classification:

    616 Diseases

Citation

Wright, G. P., Stauss, H. J., & Ehrenstein, M. R. (2011). Therapeutic potential of Tregs to treat rheumatoid arthritis. Seminars in Immunology, 23(3), 195-201. https://doi.org/10.1016/j.smim.2011.07.004

Authors

Keywords

rheumatoid arthritis, T cells, Tregs, Th17 phenotype

Monthly Views:

Available Documents